# Novartis Institute for Biomedical Research

Novartis Institute for Biomedical Research is an other based in San Francisco, United States.

## Overview

- **Organization type:** other
- **Headquarters:** San Francisco, United States
- **Region:** North America
- **Address:** San Francisco, CA, United States
- **Assets under management:** Undisclosed
- **Website:** novartis.com/research
- **LinkedIn:** https://www.linkedin.com/company/novartis-institute-for-biomedical-research

## Regulatory record

- **Reports private funds:** No

## About

The Novartis Institute for Biomedical Research (NIBR) was established as a division of Swiss pharmaceutical giant Novartis, though its exact founding year as a distinct entity is unclear. It operates as a centralized R&D engine, distinct from traditional family offices or asset managers, funded by Novartis's pharmaceutical revenues. Wealth origin traces to Novartis corporate earnings, not a private family. NIBR invests across a range of therapeutic areas including oncology, cardiovascular disease, neuroscience, and immunology. Research covers drug discovery stages from target identification through preclinical development, with a notable emphasis on AI-driven drug design, cell and gene therapies, and genomics. Confirmed initiatives include a multi-year collaboration with Alphabet's Verily to develop smart contact lenses and a partnership with the Broad Institute for genomic data analysis. Geography spans North American hubs and a major center in Shanghai, China. Total deployment by NIBR is substantial; Novartis reported $9.0 billion in R&D spending in 2023 (per Novartis, annual report 2023). The institute is not a separate legal entity with its own AUM. There is no disclosed team size for NIBR specifically, but it encompasses thousands of scientists. No philanthropic vehicles or club memberships are publicly linked to NIBR. The key structural differentiator is NIBR's pure-play R&D mandate: it is a research institute, not an investment office. Its capital is exclusively deployed into internal discovery programs, external academic partnerships, and early-stage company collaborations — no external LP fund commitments, no co-investment vehicles. This architecture is shaped by Novartis's corporate governance, with the board appointing the NIBR president, who reports to the Novartis CEO.

## Sectors

- Biotech
- Drug Discovery & Development
- AI/ML
- Genomics
- Cell & Gene Therapy

## Offices

- Princeton, NJ, United States
- Pasadena, CA, United States
- Shanghai, China

## Questions

### Who runs research decisions at NIBR?

The president of NIBR is appointed by the Novartis Board of Directors. As of 2024, the role is held by James Bradner, an oncologist and biomedical researcher who previously led the Novartis Institutes for BioMedical Research from 2017 (per Novartis, 2024).

### How does NIBR source its research programs?

Research programs originate from internal scientific discovery, academic collaborations, and partnerships with biotech firms. NIBR has structured early-stage partnerships via joint ventures and licensing deals, including its collaboration with Verily and the Broad Institute.

### What therapeutic areas does NIBR focus on?

NIBR concentrates on oncology, cardiovascular and metabolic disease, neuroscience, ophthalmology, and immunology. It also has dedicated units for cell and gene therapy, biotherapeutics, and genomics.

### Is NIBR involved in venture capital or external investments?

NIBR does not operate a venture capital arm. It does, however, partner with the Novartis Venture Fund, a separate entity that makes external equity investments in life sciences companies. NIBR itself channels all capital into internal R&D.

### Where is NIBR headquartered?

The institute has multiple global hubs. The primary research headquarters is in Cambridge, Massachusetts, with major sites in San Francisco, Princeton, Pasadena, and Shanghai, China (per Novartis, public record).

### Does NIBR publish its drug pipeline?

Yes, NIBR, as part of Novartis, discloses its full pipeline on a quarterly basis through Novartis's investor relations. The pipeline includes compounds in preclinical through Phase III trials (per Novartis, quarterly reports).

## Related profiles

- [R&H Fund Services](https://altss.com/profile/randh-fund-services)
- [Play Versus](https://altss.com/profile/play-versus)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/novartis-institute-for-biomedical-research

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology